Extended Data Fig. 2: Genomic annotation of integration sites for infusion product, post infusion timepoints < 60d and > 60d.
From: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
a, graphic of the annotation scheme. The integration sites from patient 1 (b) and 2 (c) were annotated based on its position relative to known genes (UCSC hg38) and permissive enhancers (FANTOM 5). The counts of integration sites that fall into each annotation category in infusion product were summarized (left). The mean and standard deviation of the number of sites for each category were also computed for 1–60 days post infusion (middle) and > 60 days post infusion (right).
